Researchers
-
Begoña Pina Marín
Ophthalmology
-
Carlos Luis Moser Würth
Ophthalmology
-
Carlos Martínez Belló
Ophthalmology
-
Diana Paola Mora Ramirez
Ophthalmology
-
Joan Josep Escobar Barranco
Ophthalmology
-
Josep Badal Lafulla
Ophthalmology
Phd -
Luis Amselem Gómez
Ophthalmology
-
Magela Garat Chifflet
Ophthalmology
-
Manel Fernández Bonet
Ophthalmology
-
Monica Lecumberri López
Ophthalmology
-
Rafael Alcubierre Bailac
Ophthalmology
-
Sabrina Bojados
Ophthalmology
-
Stephanie Carrillo
Ophthalmology
Contact the group
Form
Projects
-
- Year 2014
- Dos de Maig Hospital Integral Care Center
Patient satisfaction study
-
DISTRICT ATTORNEY:
Thea Laboratories
-
TYPE E:
EPA
-
- Year 2014
- Comprehensive Care Center Dos de Maig Hospital
Phase IV clinical trial to evaluate the efficacy of aflibercept in naive patients with retinal angiomatous proliferation lesions (RAP) in individualized treatment regimen Treat and Extend (TAE). AFLIRAP studio,
-
DISTRICT ATTORNEY:
Bellvitge Biomedical Research Institute (IDIBELL Foundation)
-
TYPE E:
RD2004
-
Ophthalmology
Researcher
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Phase IV clinical trial to evaluate the genetic variants of the VEGF pathway as biomarkers of the efficacy of treatment with aflibercept in patients with neovascular age-related macular degeneration (AMD),
-
DISTRICT ATTORNEY:
Research Foundation of the Institute of Ocular Microsurgery
-
TYPE E:
RD2004
-
Ophthalmology
Researcher
- Year 2013
- Comprehensive Care Center Dos de Maig Hospital
Phase IV clinical trial to evaluate the genetic variants of the VEGF pathway as biomarkers of the efficacy of treatment with aflibercept in patients with neovascular age-related macular degeneration (AMD),
-
DISTRICT ATTORNEY:
Research Foundation of the Institute of Ocular Microsurgery
-
TYPE E:
RD2004
-
Ophthalmology
Researcher
- Year 2013
- Comprehensive Care Center Dos de Maig Hospital
Retrospective observational study to determine the clinical evolution of patients with age-related macular degeneration, treated with long-term ranibizumab in routine clinical practice,
-
DISTRICT ATTORNEY:
Novartis Farmaceútica, SA
-
TYPE E:
EPA
-
Ophthalmology
Researcher
- Year 2013
- Comprehensive Care Center Dos de Maig Hospital
Unicentric retrospective observational study to describe the management of patients with visual impairment secondary to diabetic macular edema treated with ranibizumab alone or in combination with other treatments based on individualized follow-up,
-
DISTRICT ATTORNEY:
Consorci Sanitari Integral
-
TYPE E:
PI
-
Ophthalmology
Researcher
- Year 2013
- Comprehensive Care Center Dos de Maig Hospital
Study to observe the effectiveness and safety of Lucentis through the individualized treatment of the patient and the associated results,
-
DISTRICT ATTORNEY:
Novartis Pharma AG
-
TYPE E:
EPA
-
Ophthalmology
Researcher
- Year 2013
- Sant Joan Despí Moisès Broggi Hospital
Descriptive study on the management of patients with Diabetic Macular Edema and Macular Edema Secondary to Venous Occlusion of the Retina by the retinologist specialist and Adherence to the official recommendations of the Spanish Retina and Vitreous Society (SERV). Study OBSERVER.
-
DISTRICT ATTORNEY:
Novartis Farmaceútica SA,
-
TYPE E:
EPA
-
- Year 2013
- Comprehensive Care Center Dos de Maig Hospital
Phase IV clinical trial to evaluate the genetic variants of the VEGF pathway as biomarkers of the efficacy of treatment with aflibercept in patients with neovascular age-related macular degeneration (AMD),
-
DISTRICT ATTORNEY:
Research Foundation of the Institute of Ocular Microsurgery
-
TYPE E:
RD2004
-
- Year 2013
- Dos de Maig Hospital Integral Care Center
Study to observe the effectiveness and safety of Lucentis through the individualized treatment of the patient and the associated results,
-
DISTRICT ATTORNEY:
Novartis Pharma AG
-
TYPE E:
EPA
Lines of action
- Treatment of retinal diseases with intravitreal medication
- Anti VEGF in diabetic macular edema
- Anti VEGF in central serous chorioretinopathy
- Treatment of Diabetic Retinopathy
- UTI (Intravitreal Therapy Unit)
- New techniques in cataract surgery
- Surgical alternatives to full thickness corneal transplantation
- Microkeratum assisted keratoplasty Anterior and posterior lamellar techniques
